Low female birth weight and advanced maternal age programme alterations in next-generation blastocyst development

Jordanna S Master¹, George A Thouas², Alexandra J Harvey², John R Sheedy², Natalie J Hannan²,³, David K Gardner² and Mary E Wlodek¹

¹Department of Physiology and ²School of BioSciences, The University of Melbourne, Parkville, Victoria 3010, Australia and ³Department of Obstetrics and Gynaecology, Mercy Hospital, The University of Melbourne, Heidelberg, Victoria 3084, Australia

Correspondence should be addressed to M E Wlodek; Email: m.wlodek@unimelb.edu.au

Abstract

Low birth weight is associated with an increased risk for adult disease development with recent studies highlighting transmission to subsequent generations. However, the mechanisms and timing of programming of disease transmission to the next generation remain unknown. The aim of this study was to examine the effects of low birth weight and advanced maternal age on second-generation preimplantation blastocysts. Uteroplacental insufficiency or sham surgery was performed in late-gestation WKY pregnant rats, giving rise to first-generation (F1) restricted (born small) and control offspring respectively. F1 control and restricted females, at 4 or 12 months of age, were naturally mated with normal males. Second-generation (F2) blastocysts from restricted females displayed reduced expression of genes related to growth compared with F2 control (P < 0.05). Following 24 h culture, F2 restricted blastocysts had accelerated development, with increased total cell number, a result of increased trophectoderm cells compared with control (P < 0.05). There were alterations in carbohydrate and serine utilisation in F2 restricted blastocysts and F2 restricted outgrowths from 4-month-old females respectively (P < 0.05). F2 blastocysts from aged restricted females were developmentally delayed at retrieval, with reduced total cell number attributable to reduced trophectoderm number with changes in carbohydrate utilisation (P < 0.05). Advanced maternal age resulted in alterations in a number of amino acids in media obtained from F2 blastocyst outgrowths (P < 0.05). These findings demonstrate that growth restriction and advanced maternal age can alter F2 preimplantation embryo physiology and the subsequent offspring growth.


Introduction

Intrauterine growth restriction, characterised by birth weight below the 10th percentile for gestational age, complicates ~10% of all pregnancies in the Western world and is commonly caused by placental dysfunction during late gestation (Barker 1995, McMillen & Robinson 2005). Epidemiological studies have highlighted that being born small is associated with an increased disease risk not only for that individual, but also for subsequent generations of offspring (Heijmans et al. 2008, Painter et al. 2008). It has been reported that first-generation (F1) women, who themselves were undernourished in utero and born small, delivered smaller second-generation (F2) babies with an increased risk of developing hypertension, cardiovascular disease, impaired glucose tolerance and obesity in adult life (Heijmans et al. 2008, Painter et al. 2008). The pathways hypothesised to regulate transmission of disease risk include direct effects on germ cells from the F1 fetus, by inheritance through persistent epigenetic modifications of either of the parental germ cells, and/or abnormal pregnancy adaptations (Gallo et al. 2012a). However, it is unclear whether early changes in F2 physiology can be detected.

The blastocyst stage represents an early developmental window where reprogramming can occur (Watkins et al. 2008a). Before implantation, the blastocyst moves through the female reproductive tract bathed in nutrients from the surrounding maternal microenvironment and is therefore sensitive to changes in secretions in the maternal milieu. The primary sources of energy for the embryo from fertilisation to compaction are pyruvate, lactate and non-essential amino acids, while after compaction development, the utilisation of glucose and both essential and non-essential amino acids becomes increasingly important (Hardy et al. 1989, Brison & Leese 1991, Lane & Gardner 1997, Gardner 1998). Alterations in metabolic control during
pregnancy, as reported in late gestation F1 female growth-restricted offspring (Galloy et al. 2012b), may be apparent earlier in development and alter nutrient availability to the developing F2 blastocyst before implantation. These changes may lead to subsequent alterations in growth and development of the fetus and placenta. The blastocyst comprises the inner cell mass (ICM) and the trophectoderm (TE), which give rise to the fetus and extra-embryonic tissues and placenta respectively. The placenta is an essential regulator of fetal growth during gestation, providing gas and nutrients to the developing fetus. Therefore, alterations caused by impaired TE development or function may affect placental development and therefore fetal nutrition and growth, leading to the programming of disease risk in the resultant progeny.

Several studies document clear alterations in F1 preimplantation embryo physiology and development that contribute to subsequent F1 health when an insult is experienced by the mother (F0) during pregnancy. Exposure of preimplantation mouse embryos to gestational diabetes leads to reductions in intracellular glucose and glucose utilisation, resulting from reductions in glucose uptake and expression of transporters at the mRNA and protein level in F1 preimplantation embryos (Moley et al. 1998). In a rat model of diabetes, high incidences of abnormal F1 preimplantation blastocysts have been reported, where only 33% of blastocysts reached the expanded blastocyst stage with a 20% reduction in ICM cell numbers (Lea et al. 1996). Similarly, studies examining the effect of maternal low-protein diet during early gestation (0–4.25 days) in rats have reported F1 female offspring born of low birth weight, accelerated postnatal growth in both F1 male and female offspring, and the development of hypertension in F1 male offspring (Kwong et al. 2000). Assessment of the early-stage F1 preimplantation blastocyst revealed a reduction in ICM number followed by reduced ICM and TE cell number at the expanding blastocyst stage due to slowed proliferation (Kwong et al. 2000). It was concluded that due to a mildly hyperglycaemic and amino acid-depleted maternal environment, maternal undernutrition may programme metabolic stress within the blastocyst.

Abnormal glucose metabolism in the mouse blastocyst has been linked to decreased developmental and implantation potential (Lane & Gardner 1996). Provision of adequate glucose and amino acids in combination is beneficial to blastocyst development, ICM number and post-transfer fetal development, indicating that blastocyst nutrition is highly responsive to environmental metabolites. Amino acids and vitamins prevent metabolic perturbations and the associated loss of viability of mouse blastocysts (Lane & Gardner 1998). Studies have highlighted that physiological changes occur within the preimplantation blastocyst to stabilise fetal growth and promote postnatal fitness in response to maternal low-protein diet during pregnancy (Watts et al. 2008b,c). The majority of embryo programming studies have, however, focused on alterations in F1 embryos and F1 offspring health. Few studies have characterised alterations in embryo growth and development in the next (F2) generation.

Our established rat model of uteroplacental insufficiency mimics intrauterine growth restriction similar to that observed in the Western world (Wlodek et al. 2005, 2008). Both F1 male and female offspring have organ deficits, but only F1 male offspring develop hypertension and metabolic dysfunction in adult life (Wadley et al. 2008, Wlodek et al. 2008, Moritz et al. 2009). During late gestation, F1 female growth-restricted offspring become glucose intolerant, develop glomerular hypertension and have modifications in uterine artery function (Mazzuca et al. 2010, Galloy et al. 2012b). Alterations in the intrauterine nutrient environment caused by glucose intolerance may compromise F2 embryonic and fetal development, and therefore programme disease development in that generation, particularly affecting germ cell development. Altered fetal growth induced by uteroplacental insufficiency programmes F2 nephron and β-cell mass deficits, as well as hypertension and metabolic dysfunction in F2 offspring in the absence of low F2 birth weight (Anderson et al. 2006, Bertram et al. 2008, Torrens et al. 2008, Galloy et al. 2012b, 2013, Tran et al. 2013). These studies highlight that the maternal metabolic environment may significantly affect the development of the blastocyst before implantation.

Increasing age has also been strongly associated with decreased fertility in humans, leading to recurrent pregnancy loss or complications (Gindoff & Jewelewicz 1986). Maternal age, particularly after 35 years, is also associated with decreased ovarian reserve and increased rates of aneuploidy and chromosomal abnormality in their oocytes and cleavage stage preimplantation embryos (Munne et al. 1995, 2007, Harton et al. 2013). Murine models are in agreement with these changes, as increasing maternal age is related to increased rates of embryo fragmentation, although rodents do not show the same dramatic decline as humans in reproductive performance (Jurisicova et al. 1998). Maternal age, in both species, is, however, related to gestational factors such as increased placental weight (Havaldsen et al. 2011, Galloy et al. 2012c). In recent studies of advanced maternal age, we have demonstrated that this parameter leads to a similar increase in placental weight at embryonic (E) day 20, followed by reduced litter size and birth weight (Galloy et al. 2012c). However, the effect of advanced maternal age on next-generation blastocyst morphology, carbohydrate utilisation, outgrowth potential and amino acid utilisation is yet to be addressed.

Therefore, the aims of this study were to assess blastocyst growth and development, metabolism and function of F2 preimplantation rat blastocysts derived from F1 growth-restricted females induced by uteroplacental insufficiency, and to examine the effect of age on preimplantation...
blastocyst development and viability. We propose that adverse pregnancy adaptations, such as glucose intolerance and glomerular hypertrophy, in female offspring born small would lead to alterations in the development and metabolism of their preimplantation blastocysts, which may affect growth and development of offspring in the next generation.

Materials and methods

Unless otherwise stated, chemicals were obtained from Sigma.

Mating and animal generation

This study was approved by the University of Melbourne Animal Ethics Experimentation Committee before all experimental procedures were carried out (AEC 112128). A vaginal impedance reader (model MK-10B, Mukomachi Kikai, Osaka, Japan) was used to determine the time of oestrus for mating as described previously (Wlodek et al. 2005, 2008). Female WKY rats (F0) were mated between 18 and 24 weeks of age. On day 18 of gestation, rats underwent sham (control) or bilateral uterine vessel ligation (restricted) surgery (Wlodek et al. 2005, 2008). Rats gave birth naturally at term (day 22) to F1 control and growth-restricted offspring (born small) respectively. After weaning, day 35, F1 females were removed from F0 mothers and housed with one to two other females until the time of mating. Body weights and dimensions were measured in F1 females at day 1, day 7, day 35, 2 months, 3 months and 4 months of age (Wlodek et al. 2007).

F1 control and restricted females, at 4 months (n = 10/group) or 12 months (aged line) (n = 10/group) of age at oestrus, were naturally mated with normal (F0) males. For all experimental groups, one female per litter was used. Three sets of females were generated for gene analyses (n = 6/group; performed in the 4-month cohort only), blastocyst morphology and carbohydrate utilisation (n = 6/group) and outgrowth and amino acid utilisation (n = 6/group). Mating success was confirmed by the presence of a vaginal plug after mating, and the following morning was considered day 0.5 of pregnancy. All female body weights and dimensions were measured before mating and at postmortem (day 4.5 of pregnancy) (Wlodek et al. 2005, 2008) after they were killed by CO2 inhalation. Plasma insulin concentrations were measured in duplicate using a rat insulin RIA kit (Millipore, Abacus ALS, Brisbane, QLD, Australia) (Tran et al. 2013). Plasma glucose concentrations were measured in duplicate using a scaled-down version of the enzymatic fluorometric analysis (Tran et al. 2013).

RT2 profiler PCR array analysis

Total RNA was extracted from three independent biological replicates of blastocysts using the Roche Total RNA Isolation Kit (Roche) according to the manufacturer instructions performed in the 4-month cohort only. There were six females per group and 10–20 blastocysts were pooled from two mothers resulting in three independent biological replicates per group. Briefly, samples were lysed and bound to a silica-based filter where they were treated with RNase-free DNase I (Roche), then washed with the kit buffer before elution in 50 µl of the kit elution buffer. RNA concentration was assessed using a NanoDrop absorbance spectrophotometer (ND1000, ThermoScientific, Waltham, MA, USA) and RNA integrity was evaluated with the Agilent 2100 Bioanalyzer using a RNA 6000 Nano Assay Kit (Agilent Technologies, Santa Clara, CA, USA). RNA was converted to cDNA using the RT2 First Strand cDNA synthesis kit (Qiagen), and amplified using a RT2 PreAMP cDNA synthesis kit (Rat mTOR Signalling PCR array and Rat Insulin Signalling Pathway PCR array, Qiagen) according to the manufacturer’s instructions. Gene expression of mammalian target of rapamycin (mTOR) (84 genes in total, data not shown) and insulin signalling (84 genes in total, data not shown) pathways were analysed on respective RT2 Profiler Arrays (Qiagen). Amplification was performed on an ABI Viia7 (Applied Biosystems Life Technologies) with the resultant gene expression analysed using the Web-based PCR Array Data Analysis software (www.SAbiosciences.com). All significant gene expression data, summarised in the PI3K, PKB/AKT, growth and motility and metabolism and inflammation pathways, are presented and include other relevant genes in the respective pathways.

Blastocyst flushing and culture

Day 4.5 blastocysts were retrieved from intact uteri by flushing with laboratory-made MOPS buffered G2 medium modified for the rat by increasing the osmolality to 310 mOsmol/kg using NaCl, as described previously (n = 30–60 blastocysts/group from n = 6 females/group) (Oh et al. 1998, Gardner & Lane 2014). Blastocysts from F1 control and restricted females were then cultured in laboratory-made NaHCO3-buffered G2 medium (Gardner & Lane 2014) also with modified osmolality, supplemented with 5 mg/ml human serum albumin (HSA, Vitrolife, Västra Frölunda, Göteborg, Sweden) under paraffin oil (Ovoil, Vitrolife, Västra Frölunda) and housed in a dual gas incubator (TheraForma, Mariette, OH, USA) at 37 °C, in an atmosphere of 6% CO2, 5% O2 and 89% N2, for 24 h (Oh et al. 1998, Lane & Gardner 2004, Gardner & Lane 2007). F2 blastocysts were scored for the stage of development at flushing and again after the 24 h culture period, according to a numerical grade based on blastocyst morphology (grade 3, early blastocyst; grade 4, expanded blastocyst; grade 5, hatching blastocyst and grade 6, fully hatched blastocyst) (Gardner et al. 2000). Following 24 h culture, preimplantation blastocysts were prepared for differential nuclear staining or outgrowth culture.

Differential nuclear staining

Total cell number and the proportion of TE and ICM cells were assessed in F2 rat blastocysts using a modification of a method described previously (n = 30–60 blastocysts/group from n = 6 females/group) (Handyside & Hunter 1984, Hardy et al. 1989). Briefly, blastocysts were incubated in pronase (Sigma, 0.5% in GMOPS, 5 min at 37 °C) to remove the zona pellucida, then incubated in picrosulphonic acid (Sigma, 10 min at 37 °C) and washed in GMOPS with 5 mg/ml HSA. Embryos were then incubated in anti-dinitrophenol with 5 mg/ml HSA. Following 10 min at 37 °C) followed by washing in GMOPS supplemented with 5 mg/ml HSA.
Complement-mediated lysis was performed by a short incubation in guinea pig serum (IMVS, Adelaide, SA, Australia, 10 min) before transfer to a bisbenzimide solution of 0.1 mg/ml (Hoescht 33 342, Sigma). Blastocysts were then mounted in glycerol and nuclei counted under u.v. light (filter) using an inverted microscope (TS100-F, Nikon, Yamato, Kanagawa, Japan).

**Blastocyst glucose consumption and lactate production quantification**

Spent culture medium samples were stored at −80 °C following 24 h of incubation with individual F2 blastocysts (n=30–60 blastocysts/group from n=6 females/group). Glucose and lactate concentrations were measured using enzyme-linked assays described by Gardner & Leese (1987) and Gardner (2007). F2 blastocysts were first incubated in 4 μl drops of incubation medium, comprising HCO$_3^-$ buffered G2 formulated with 0.5 mM glucose as the sole substrate and no added lactate or pyruvate. Following the 24-h incubation, glucose consumption and lactate production were quantitated per embryo using a NanoDrop fluorospectrometer (ND3300, Thermo Scientific) (expressed in mol) and normalised to the number of cells per embryo to account for differences in blastocyst cell numbers. Glycolytic activity (lactate/glucose per cent ratio) of each embryo was calculated on the assumption that 2 mol of lactate are formed from 1 mol of glucose (Lane & Gardner 1996).

**Blastocyst outgrowth culture**

Outgrowths in F2 blastocysts were performed as described previously (n=10–40 blastocysts/group from n=6 females/group) (Hannan et al. 2011). Flat-bottomed 96-well plates (BD Biosciences, San Jose, CA, USA) were coated with fibronectin (10 μg/ml; Sigma) and incubated with 4 mg/ml BSA (Sigma) for 1 h. Wells were washed and filled with 150 μl of a modified G2 medium supplemented with 5 mg/ml HSA (Vitrolife, Västra Frölunda) and equilibrated at 37 °C under paraffin oil for 3 h. Hatched blastocysts were placed individually into coated wells and incubated for a period of 66 h. Blastocyst outgrowth was examined through the acquisition of images taken at 10 μl aliquots of spent outgrowth media were collected for NMR analysis. Spectra were transformed and phase corrected, and calibrated to the DSS signal (δ 0 ppm) and then lock to deuterium (D2O) and gradient shimmed. Spectra were collected over 64k data points and 256 scans. A one-dimensional nuclear overhauser spectroscopy pulse sequence with presaturation (noesypr1d) for water suppression was used (recycle delay-90°-τ-90°-τm-90°-acquire FID), with a recycle delay of 1.5 s, mixing time (τm) of 50 μs and transmitter frequency offset of 2848 Hz. Spectra were Fourier transformed and phase corrected, and calibrated to the DSS signal at 0.00 ppm. A line-broadening factor of 0.5 Hz was applied to all spectra. Processed NMR spectra were imported into the Chenomx NMR Suite v. 5.1 (Chenomx, Inc., Edmonton, AB, Canada) and medium components were identified and quantified using the 600 MHz compound library. The NMR data acquisition and processing parameters were selected to maintain compatibility with the Chenomx metabolite library as described previously (Sheedy et al. 2010).

**Statistical analyses**

All developmental, gene expression and microfluorescence data were analysed using a two-way ANOVA (SPSS, Inc.) to determine the main effects of experimental groups. If a significant interaction was detected, the Mann–Whitney’s U tests (SPSS, Inc.) were performed for *post hoc* comparisons. For all NMR data, metabolite concentrations were normalised by blastocyst outgrowth area (Constant Sum normalisation) to determine differences in metabolic flux due to blastocyst size (Webb-Robertson et al. 2005, Craig et al. 2006). As outgrowths can have bi/multi-nucleated cells, cell number estimation may be inaccurate. A data matrix of quantified metabolites from 1H-NMR spectral analysis of all samples was created. Scedasticity was corrected using log$_{10}$ transformation. All data were analysed using a two-way ANOVA (SPSS, Inc.) to determine the main effects of experimental groups. If a significant interaction was detected, the Mann–Whitney’s U tests (SPSS, Inc.) were performed for *post hoc* comparisons. In addition, the Mann–Whitney’s U tests (SPSS, Inc.) were conducted to determine significant interactions between experimental groups F2 control and restricted outgrowth medium samples from 4- and 12-month-old F1 females. Metabolite concentrations are expressed as μM/pixel$^3×10^{15}$ ± S.E.M., with metabolite concentrations expressed as production (positive values) or consumption (negative values) relative to the control medium sample. All data are expressed as means ± S.E.M. and *P*<0.05 was considered statistically significant.
Results

Uteroplacental insufficiency affects physiology of F1 females

F1 growth-restricted female offspring arising from F0 mothers that underwent bilateral uterine vessel ligation surgery were born small and remained 7–13% smaller at day 7 and day 14 compared with F1 control offspring ($P<0.05$; Table 1). The 12-month control and restricted cohort had a slight increase in body weight at 35 days and 2 months of age compared with the 4-month cohort, but there were no differences in body weight between F1 control and restricted females at 3 and 4 months of age in the 4- or 12-month cohort (Table 1). At postmortem, in the 4- and 12-month cohort, there were no differences in the relative heart, liver, pancreas, dorsal fat, uterus and ovary weights between F1 control and restricted females; however, the kidney and mammary weights were reduced in F1 restricted females ($P<0.05$; Table 1). In the 12-month cohort compared with the 4-month cohort, regardless of growth restriction, F1 females had increased heart, kidney, liver and ovary weights ($P<0.05$; Table 1). At mating, in the 4- and 12-month cohort, no differences in maternal age, weight, basal plasma glucose, basal plasma insulin, mating success rate or the number of blastocysts collected were observed between F1 control and restricted females (Table 2). F1 females in the 12-month cohort had an increase in body weight and age compared with F1 females in the 4-month cohort ($P<0.05$; Table 2). These results were collected from females allocated to the cohort of blastocyst morphology and carbohydrate utilisation measures.

Growth restriction of F1 females alters F2 blastocyst physiology

The morphological stage of blastocyst development upon retrieval at day 4.5 of gestation was not significantly different between F2 control and restricted...

---

**Table 1** F1 female body and organ weights.

<table>
<thead>
<tr>
<th></th>
<th>4-month cohort</th>
<th>12-month cohort</th>
<th>Two-way ANOVA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>Restricted</td>
<td>Group</td>
</tr>
<tr>
<td>Body weight (g)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1</td>
<td>4.27±0.08</td>
<td>3.73±0.10</td>
<td></td>
</tr>
<tr>
<td>Day 7</td>
<td>10.69±0.34</td>
<td>8.72±0.67</td>
<td>10.29±0.63</td>
</tr>
<tr>
<td>Day 14</td>
<td>22.61±0.67</td>
<td>19.45±1.52</td>
<td>23.19±0.84</td>
</tr>
<tr>
<td>Day 35</td>
<td>69.07±1.45</td>
<td>65.32±1.23</td>
<td>79.29±2.33</td>
</tr>
<tr>
<td>2 months</td>
<td>147.12±2.13</td>
<td>146.71±5.76</td>
<td>165.11±6.20</td>
</tr>
<tr>
<td>3 months</td>
<td>199.35±4.01</td>
<td>189.41±4.63</td>
<td>206.52±6.88</td>
</tr>
<tr>
<td>4 months</td>
<td>214.98±2.91</td>
<td>205.07±5.92</td>
<td>221.17±4.79</td>
</tr>
<tr>
<td>Relative organ weight (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart</td>
<td>0.42±0.01</td>
<td>0.39±0.01</td>
<td>0.99±0.02</td>
</tr>
<tr>
<td>Kidney</td>
<td>0.67±0.01</td>
<td>0.64±0.01</td>
<td>0.65±0.02</td>
</tr>
<tr>
<td>Liver</td>
<td>4.60±0.18</td>
<td>4.44±0.08</td>
<td>4.02±0.27</td>
</tr>
<tr>
<td>Pancreas</td>
<td>0.26±0.01</td>
<td>0.31±0.04</td>
<td>0.73±0.06</td>
</tr>
<tr>
<td>Mammary</td>
<td>0.25±0.03</td>
<td>0.17±0.03</td>
<td>0.32±0.07</td>
</tr>
<tr>
<td>Dorsal fat</td>
<td>1.21±0.06</td>
<td>1.15±0.04</td>
<td>4.02±0.94</td>
</tr>
<tr>
<td>Uterus</td>
<td>0.14±0.01</td>
<td>0.14±0.01</td>
<td>0.15±0.01</td>
</tr>
<tr>
<td>Ovary</td>
<td>0.11±0.01</td>
<td>0.11±0.01</td>
<td>0.07±0.01</td>
</tr>
</tbody>
</table>

F1 body weight (from birth to 4 months of age) and organ weights at postmortem (relative to body weight; day 4.5 of pregnancy) from 4- and 12-month F1 control and restricted cohort. All data are expressed as mean±s.e.m., n=10/group. $P<0.05$ vs control group (main effect). $P<0.05$ vs 4-month cohort (main effect).

**Table 2** F1 maternal parameters at mating.

<table>
<thead>
<tr>
<th></th>
<th>4-month cohort</th>
<th>12-month cohort</th>
<th>Two-way ANOVA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>Restricted</td>
<td>Group</td>
</tr>
<tr>
<td>Age (weeks)</td>
<td>21.1±1.35</td>
<td>20±0.91</td>
<td></td>
</tr>
<tr>
<td>Weight (g)</td>
<td>228.31±2.43</td>
<td>217.21±3.01</td>
<td>249.98±9.99</td>
</tr>
<tr>
<td>Plasma glucose</td>
<td>17.51±2.21</td>
<td>17.61±2.31</td>
<td>13.72±1.08</td>
</tr>
<tr>
<td>(mmol/l)</td>
<td>1.65±0.17</td>
<td>2.35±0.41</td>
<td>2.03±0.33</td>
</tr>
<tr>
<td>Plasma insulin</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>(ng/ml)</td>
<td>7±0.41</td>
<td>6±0.65</td>
<td>7±1.85</td>
</tr>
</tbody>
</table>

Measurements were performed in 4- and 12-month control and restricted cohorts. All data are expressed as mean±s.e.m., n=10/group. $P<0.05$ vs 4-month cohort (main effect).
blastocysts from 4-month-old females (Fig. 1A). However, following 24 h of incubation in vitro, F2 restricted blastocysts, from 4-month-old females, displayed accelerated development, with a higher proportion of blastocysts developing to both the hatching and fully hatched blastocyst stages compared with control blastocysts, which remained at the hatching stage (P < 0.05; Fig. 1B). F2 restricted blastocysts collected from 12-month-old (aged) F1 females were delayed in their development, with mostly early blastocysts observed on day 4.5 compared with control females, with collection of mostly expanded blastocysts after flushing (P < 0.05; Fig. 1A). Following 24 h in vitro culture, there were no differences in development to the hatching blastocyst stage between F2 control and restricted blastocysts from 12-month-old females (Fig. 1B). F2 blastocysts from F1 aged females, however, were more advanced (developmental stage 5–6), irrespective of growth restriction, compared with blastocysts from 4-month-old females (developmental stage 4–5, P < 0.05; Fig. 1B).

This growth acceleration in F2 restricted blastocysts from 4-month-old females was associated with a greater total cell number, compared with F2 control blastocysts, over the same 24 h period (P < 0.05; Fig. 2A). There was a greater TE cell number (11%, P < 0.05; Fig. 2B), while ICM cell number remained constant (Fig. 2C). The proportion of ICM:TE was not different (data not shown). A lower total cell number and TE cell number was observed in F2 restricted blastocysts from aged F1 restricted females vs F2 control blastocysts (16–19%, P < 0.05; Fig. 2A and B). F2 control blastocysts from aged F1 females had a higher number of total and TE cells compared with control blastocysts from 4-month-old females (P < 0.05; Fig. 2A and B). No differences in ICM cell number (Fig. 2C), or the ratio of ICM:TE cells (data not shown), were detected between F2 control or restricted blastocysts from either age group.

No differences were observed between F2 control and restricted blastocysts from 4-month-old females after the 24 h incubation, in either glucose consumption per hour, or when normalised to the total cell number (Fig. 3A and B). However, a significant increase was detected in lactate production by F2 restricted blastocysts from 4-month-old females compared with F2 control.
blastocysts ($P<0.05$; Fig. 3C), although this difference was not present when lactate production was expressed per cell. Glycolytic rate was not significantly different between F2 control and restricted blastocysts from 4-month-old females (Fig. 3E and F). An increase in glucose consumption per blastocyst was observed in F2 restricted blastocysts from aged F1 females, compared with the 12-month control and 4-month restricted groups at 24 h ($P<0.05$; Fig. 3A). This difference was maintained when glucose consumption was normalised to the total cell number ($P<0.05$; Fig. 3B). Neither lactate consumption nor glycolytic rate was significantly different between F2 restricted and control blastocysts from aged F1 females (Fig. 3C, D, E and F). However, lactate production per blastocyst and that per cell were both higher in the maternal 12-month cohort compared with the maternal 4-month cohort ($P<0.05$; Fig. 3C and D).

Following outgrowth culture, all F2 blastocysts attached regardless of their maternal origin (from either 4- or 12-month-old F1 females). F2 blastocyst outgrowth area did not significantly differ between F2 control and restricted groups from 4- and 12-month-old F1 females, at any of the time-points assessed (Fig. 4). There were no alterations in carbohydrate utilisation between F2 control and restricted outgrowths. Analysis of amino acid utilisation by F2 restricted outgrowths from 4-month-old females revealed an increase in lysine and serine consumption, and an increased production of

Figure 3 F2 carbohydrate consumption. (A) Glucose consumption per hour per blastocyst, (B) glucose consumption per hour per cell, (C) lactate production per hour per blastocyst, (D) lactate production per hour per cell, (E) glycolytic rate per hour per blastocyst and (F) glycolytic rate per hour per cell of F2 blastocysts following 24 h culture from 4- and 12-month F1 control and restricted cohorts. All data are expressed as mean±s.e.m., $n=30–60$ blastocysts/group from $n=6$ females/group. $P<0.05$ vs control group (main effect). $P<0.05$ vs 4-month cohort (main effect). $P<0.05$ vs control group (following significant interaction). $P<0.05$ vs 4-month cohort (following significant interaction).

www.reproduction-online.org
Genes involved in PI3K signalling, females (in F2 control and restricted blastocysts from 4-month-old signalling pathways was significantly reduced on day 4.5. Expression of genes involved in growth and insulin consumption of arginine, isoleucine, methionine, glycine, proline and tyrosine, compared with 4-month-old females. These data demonstrate that the next-generation preimplantation blastocyst is programmed via the maternal line of transmission and age. These alterations in blastocyst development and function may represent a mechanistic pathway contributing to the altered cardiovascular and metabolic phenotypes of next-generation F2 offspring, as reported previously (Gallo et al. 2012b,c, 2013).

**Discussion**

This study identifies alterations in the expression of genes involved in growth and development pathways, accompanied by increased proliferation of the trophectoderm, altered lactate metabolism and amino acid consumption of serine by F2 blastocysts arising from females born small due to intrauterine growth restriction. Advanced maternal age alters F2 preimplantation blastocyst growth and development with alterations in blastocyst cell number as well as altered carbohydrate and amino acid metabolism in arginine, isoleucine, leucine, methionine, valine, cysteine, glycine, proline and tyrosine, compared with 4-month-old females. The phenomenon of catch-up growth, with or without the combination of low birth weight, is known to programme disease development in offspring during adult life (Eriksson et al. 2001). In this study, F1 growth-restricted females were born small and displayed catch-up growth to reach a similar weight to control animals, consistent with epidemiological and experimental evidence (McMillen & Robinson 2005). F1 growth-restricted females have normal reproductive potential and basal glucose and insulin levels with unknown metabolic function. However, this is not indicative of changes that may be occurring in the uterine circulation and lumen. We have also previously reported no alterations in F2 litter size, which is indicative of maintenance of pregnancy by F1 growth-restricted females (Gallo et al. 2012b). While these experiments demonstrate that there are no differences in birth weight of F2 restricted offspring, cellular deficits and programming of metabolic disease and hypertension occur in a sex-specific manner in F2 offspring (Włodek et al. 2008, Moritz et al. 2009, Mazzauc et al. 2010, Gallo et al. 2012b). Importantly, we have previously demonstrated loss of glucose tolerance during late gestation in F1

**Uteroplacental insufficiency does not affect reproductive fitness of F1 females**

Growth restriction of F1 females alters F2 blastocyst gene expression dynamics

Expression of genes involved in growth and insulin signalling pathways was significantly reduced on day 4.5 in F2 control and restricted blastocysts from 4-month-old females (P<0.05; Fig. 5: total of 168 genes targeted). Genes involved in PI3K signalling, Pik3ca and Pik3cb, had reduced expression in F2 restricted blastocysts compared with controls (26–32%, P<0.05; Fig. 5A). Energy-sensing pathway genes, Prkag1, Prkcb, Tsc1, Rraga, Mtor and Ulk1, involved in PKB/Akt signalling, were significantly reduced in F2 restricted blastocysts (30–97%, P<0.05; Fig. 5B). Expression of growth and motility genes Actb and Prl was reduced (31–53%, P<0.05; Fig. 5C); however, Ras gene expression was significantly increased in F2 restricted blastocysts compared with controls (110%, P<0.05; Fig. 5C). F2 restricted blastocysts also displayed reduced expression of genes involved in metabolism, Ldha and Ucp1 (38–77%, P<0.05; Fig. 5D) compared with maternal 4-month control blastocyst levels (Figure 4).
Table 3 F2 outgrowth blastocyst nutrient utilisation.

<table>
<thead>
<tr>
<th>Metabolite</th>
<th>4-month cohort (pmol/blastocyst/h/ (pixels²10³))</th>
<th>12-month cohort (pmol/blastocyst/h/ (pixels²10³))</th>
<th>Two-way ANOVA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>Restricted</td>
<td>Control</td>
</tr>
<tr>
<td>Glucose</td>
<td>−28.7 ± 8.15</td>
<td>−20.15 ± 5.64</td>
<td>0.18 ± 1.49</td>
</tr>
<tr>
<td>Lactate</td>
<td>−22.26 ± 8.08</td>
<td>−15.42 ± 6.62</td>
<td>8.74 ± 1.87</td>
</tr>
<tr>
<td>Pyruvate</td>
<td>0.41 ± 0.10</td>
<td>0.30 ± 0.09</td>
<td>0.05 ± 0.02</td>
</tr>
<tr>
<td>Essential amino acids</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arginine</td>
<td>−2.94 ± 1.26</td>
<td>−3.64 ± 0.61</td>
<td>−0.55 ± 0.90</td>
</tr>
<tr>
<td>Histidine</td>
<td>−0.44 ± 0.20</td>
<td>0.26 ± 0.22</td>
<td>0.19 ± 0.16</td>
</tr>
<tr>
<td>Isoleucine</td>
<td>−1.58 ± 0.41</td>
<td>−1.67 ± 0.30</td>
<td>0.07 ± 0.24</td>
</tr>
<tr>
<td>Leucine</td>
<td>−1.79 ± 0.54</td>
<td>−1.73 ± 0.28</td>
<td>−0.01 ± 0.13</td>
</tr>
<tr>
<td>Lysine</td>
<td>−0.26 ± 0.90</td>
<td>−3.13 ± 0.43</td>
<td>−0.03 ± 0.28</td>
</tr>
<tr>
<td>Methionine</td>
<td>−0.27 ± 0.09</td>
<td>−0.20 ± 0.05</td>
<td>0.08 ± 0.06</td>
</tr>
<tr>
<td>Phenylalanine</td>
<td>−0.75 ± 0.21</td>
<td>−0.19 ± 0.20</td>
<td>−0.10 ± 0.15</td>
</tr>
<tr>
<td>Threonine</td>
<td>0.29 ± 0.26</td>
<td>0.40 ± 0.26</td>
<td>0.47 ± 0.52</td>
</tr>
<tr>
<td>Valine</td>
<td>−1.76 ± 0.51</td>
<td>−1.48 ± 0.27</td>
<td>−0.10 ± 0.15</td>
</tr>
<tr>
<td>Non-essential amino acids</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alanine</td>
<td>−0.10 ± 0.25</td>
<td>0.26 ± 0.15</td>
<td>0.30 ± 0.11</td>
</tr>
<tr>
<td>Asparagine</td>
<td>0.22 ± 0.26</td>
<td>0.18 ± 0.35</td>
<td>0.02 ± 0.08</td>
</tr>
<tr>
<td>Aspartate</td>
<td>0.22 ± 0.36</td>
<td>0.94 ± 0.54</td>
<td>0.09 ± 0.14</td>
</tr>
<tr>
<td>Cysteine</td>
<td>1.12 ± 0.29</td>
<td>1.30 ± 0.41</td>
<td>0.18 ± 0.14</td>
</tr>
<tr>
<td>Glutamate</td>
<td>−0.03 ± 0.30</td>
<td>0.16 ± 0.31</td>
<td>0.15 ± 0.10</td>
</tr>
<tr>
<td>Glycine</td>
<td>−4.26 ± 1.29</td>
<td>−5.77 ± 1.84</td>
<td>1.47 ± 1.41</td>
</tr>
<tr>
<td>Proline</td>
<td>−3.10 ± 0.86</td>
<td>−0.42 ± 0.91</td>
<td>1.18 ± 0.40</td>
</tr>
<tr>
<td>Serine</td>
<td>0.01 ± 0.27</td>
<td>0.12 ± 0.39</td>
<td>0.13 ± 0.20</td>
</tr>
<tr>
<td>Tyrosine</td>
<td>−0.40 ± 0.14</td>
<td>−0.61 ± 0.20</td>
<td>−0.05 ± 0.09</td>
</tr>
</tbody>
</table>

Measurements were performed on F2 blastocysts from 4- and 12-month control and restricted cohorts. Metabolite concentrations expressed as production (positive values) or consumption (negative values) relative to the media only sample. All data are expressed as mean ± s.e.m.; n = 10–40 blastocysts/group from n = 6 females/group. P<0.05 vs 4-month cohort (main effect), *P<0.05 vs control group (following significant interaction) and †P<0.05 vs 4-month cohort (following significant interaction). ‡P<0.05 vs control and §P<0.05 vs 4-month cohort.

growth-restricted mothers at 4 months of age (Mazzuca et al. 2010, Gallo et al. 2012b). The onset and timing of these alterations may affect next-generation embryonic and fetal development.

**Accelerated growth in F2 blastocysts**

F2 restricted blastocysts accelerate growth when placed into *in vitro* culture, 24 h after retrieval. This growth was associated with a greater TE cell number, which may be responsible for the increase in lactate production. Significantly, over-production of lactate alone has been correlated with lower implantation potential in mouse blastocysts grown *in vitro* (Lane & Gardner 1996). Previous studies using rat embryos have indicated that nutrient imbalances can affect rat embryo metabolism and alter normal cellular function (Lane & Gardner 1998). Adaptation to the *in vitro* culture environment is reported to be associated with a higher ratio of TE to ICM, and as a result reduced viability (Hurst et al. 1993). Accelerated blastocyst and increased total cell number, attributed to greater TE cell number, may therefore be indicative of an adaptation to the culture environment in order to maintain the integrity of the ICM.

When F2 restricted blastocysts were placed in outgrowth culture, alterations in carbohydrate and amino acid metabolism were observed. Outgrowth of blastocysts revealed increases in the consumption of amino acids, specifically serine and lysine, which may reflect the metabolic changes detected at 24 h, due to increased lactate secretion, probably from TE cells. Serine consumption has been shown to act on intracellular growth factors and extracellular matrix proteins to favour correct formation and function in placental cells (De et al. 2004). Regulation of serine utilisation may be required for the initial short-term increased growth of F2 restricted blastocysts immediately following flushing, which is then maintained and stabilised at later time-points, reflected as no difference in the outgrowth area of F2 blastocysts. Such alterations in blastocyst metabolism and amino acid profiles that drive cell proliferation and differentiation would have significant implications for the development of the nutrient transport systems within the developing placenta, especially during trophoblast differentiation from the TE (Fowden et al. 2008). Glutamate production was increased, which may reflect reduced intracellular storage within the blastocyst. Glutamate has been reported to be important for placental and fetal metabolism as it generates NADPH for placental fatty acid steroid synthesis (Moore et al. 1994, Vaughn et al. 1995). Human intrauterine growth restriction studies are characterised by reduced fetal plasma concentrations of essential amino acids such as valine, leucine, isoleucine and lysine (Cetin et al. 1988, Avagliano et al. 2012). A reduction in uptake of lysine in the placenta due to reduced system A amino acid transport activity has also been demonstrated in pregnancies complicated by intrauterine growth restriction (Dicke & Henderson 1988, Jansson et al. 1998).
It is not known whether alterations in amino acid levels in the F1 restricted uterine environment exist, which may subject the F2 restricted blastocyst to an altered nutrient environment. Low nutrient availability or absorption can alter signalling pathways, which will affect growth and development of the preimplantation blastocyst (Hardy et al. 1989, Brison & Leese 1991, Lane & Gardner 1997, Gardner 1998). Conversely, transition from low to high nutrient availability can trigger an adaptive response.

Amino acids are also required for TE motility through the activation of mTOR-dependent signal cascades (Martin & Sutherland 2001, Martin et al. 2003). Regulated by amino acids, the mTOR pathway is responsible for cell growth, proliferation, motility, protein synthesis and transcription. The day 4.5 F2 restricted blastocysts exhibited significant reductions in expression of \( \text{Pi3k} \) genes, kinases and binding genes (\( \text{Prkra's} \) and \( \text{Tsc1} \), \( \text{Mtor} \) and growth-related genes (\( \text{Ulk1} \) and \( \text{Prl} \)) in the mTOR growth pathway. The downstream events of PI3K signalling are mediated by serine/threonine protein kinase B (PKB/Akt) (Datta et al. 1999, Blume-Jensen & Hunter 2001, Han & Carter 2001). Loss or reduction in PKB activity has been related to defects in growth and development of the placenta, placental insufficiency, and results in impaired growth and motility.

**Table 4 RT2 profiler arrays.**

<table>
<thead>
<tr>
<th>mTOR signalling</th>
<th>Insulin signalling</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akt1, Akt1s1, Akt2, Akt3, Cab39, Cal539l, Cdcd88b, Cdc42, Chuk, Ddit4, Ddit4l, Eif4b, Eif4e, Eif4ebp1, Eif4ebp2, Fkbp1a, Fkbp8, Gsk3b, Hif1a, Hras, Hspa4, Igf1, Igfbp3, Ikkb, Ilk, Ins2, Irs1, Kras, Mapk1, Mapk3, Mapkap1, Mst6, Mtor, Myo1c, Nras, Pik3c3, Pik3ca, Pik3cb, Pik3cg, Pik3r2, Pld1, Pld2, Ppp2ca, Ppp2rb2, Ppp2r4, Prkaa1, Prkaa2, Prkab1, Prkab2, Prkag1, Prkag2, Prkag3, Prkca, Prkcb, Prkce, Prkgc, Pten, Rheb, Rheoa, Rps6, Rps6ka1, Rps6ka2, Rps6ka5, Rps6kb1, Rps6kb2, Raptor, Ragra, Rragb, Rragc, Rragd, Sgg1, Sgg11, Tp53, Tsc1, Tsc2, Ulk1, Vegla, Veglb, Veglc, Ywhaq, Actb, B2m, Hprt1, Ldha, and Rplp1</td>
<td>Acaca, Acox1, Adra1d, Aebp1, Akt1, Akt2, Akt3, Araf, Bcl2l1, Braf, Cap1, Cbl, Cebpa, Cebp, Ctr1, Dok1, Dok2, Dok3, Dusp14, Eif2b1, Eif4ebp1, Ercc1, Fas, Fbn1, Fos, Frs2, Frs3, G6pc, Gab1, Gcg, Gck, Gpd1, Grb10, Grb2, Gsk3b, Hk2, Hras, Igf1r, Igf2, Igfbp1, Ins1, Ins2, Irs1, Irs2, Jun, Klf10, Kras, Ldlr, Lep, Map2k1, Mapk1, Mtor, Nos2, Npy, Pck2, Pdp1, Pik3ca, Pik3cb, Pik3r2, Pikr, Pparg, Ppp1ca, Pikcg, Prkcz, Pp, Ppyn1, Raf1, Retn, Rps6ka1, Ras, Ras2, Serpinel1, Shc1, Slc27a4, Slc2a1, Slc2a4, Sos1, Sreb1, Tg, Ucp1, Vegla, Actb, B2m, Hprt1, Ldha and Rplp1</td>
</tr>
</tbody>
</table>

**Figure 5** F2 day 4.5 gene expression. Measurements performed on F2 blastocysts from 4-month F1 control and restricted females. Relative gene expression of (A) \( \text{Pi3k} \) signalling, (B) \( \text{Pkb/Akt} \) signalling, (C) growth and motility and (D) energy metabolism and inflammation to control level (1, dotted line). All data are expressed as mean ± s.e.m. There were six females per group and 10–20 blastocysts were pooled from two mothers resulting in three independent biological replicates/group. *\( P < 0.05 \) vs control, **\( P < 0.01 \) vs control and ***\( P < 0.001 \) vs control.
fetal growth (Yang et al. 2003). Reduced mTORC1 activity was reported in F1 mouse blastocysts from mothers subjected to maternal undernutrition (0–4.25 days) during pregnancy (Eckert et al. 2012). As gene expression analysis was performed on blastocysts retrieved from F1 growth-restricted females, this clearly highlights pre-existing (epi)genetic alterations that could affect blastocyst metabolism. Limited availability of blastocyst material precluded validation of alterations in protein expression. Epigenetic modifications to F1 germ cells or alterations in F1 germ cells, due to the initial insult of growth restriction, may directly affect F2 blastocyst growth and development and consequently placental and fetal growth.

**Age-related alterations in F2 blastocysts**

‘Second-hits’, such as advanced maternal age, are known to highlight growth restriction phenotypes in female offspring (Nenov et al. 2000). However, we have demonstrated that with advanced maternal age, basal glucose homeoeostasis, ovarian function and reproductive potential remain normal in the rat (Gallo et al. 2012c). We have previously reported that advanced maternal age, regardless of growth restriction, results in reduced F2 fetal weight (E20) and litter size (Gallo et al. 2012c). These data indicate that although mating success appears normal in aged females, it is not necessarily a reflection on ovarian function and oocyte, as fetal loss can also be attributed to inadequate placental function.

F1 growth-restricted female rats, with advanced age at conception, produced blastocysts with delayed morphological development and lower cell numbers, which is likely to be attributed to lower TE cell number. The same blastocysts also showed an unusual adaptive metabolic response, this time reflected in an increased glucose uptake, but no change in lactate output. This is curious, as increased glucose uptake correlates positively with blastocyst implantation potential in the mouse and human (Gardner et al. 2011). In our case, the higher glucose consumption in blastocysts with lower TE cell numbers is potentially a very sudden adaptive response to meet the demands of timely blastocoele expansion. Indeed, the speed of blastocoele fluid accumulation is positively correlated with glucose uptake in rat blastocysts (Brison & Leese 1994). Furthermore, glucose uptake may lead to increased glucose accumulation in the blastocoele itself, rather than being metabolised (Brison et al. 1993), which would explain the lack of change in lactate production. The glucose adaptation may also be reflective of the sustained alterations in carbohydrate and amino acid metabolism observed during blastocyst outgrowth. Of note is the reversal of aspartate levels from its production in the aged restricted blastocyst outgrowths, to its consumption in the controls. Aspartate is highly consumed by mouse blastocysts, and blockage of this amino acid from entering the citric acid cycle has been reported to lead to impaired fetal development (Mitchell et al. 2009).

Altered carbohydrate metabolism has similarly been linked to abnormalities in fetal development and in some cases loss of pregnancy in both humans and murine models (Jurisicova et al. 1998, Harton et al. 2013). Studies have highlighted that oocytes and blastocysts from older females present with chromosomal abnormalities or maladaptation of the embryo in the absence of chromosomal abnormalities (Munne et al. 1995, 2007, Harton et al. 2013), which may explain the reduction in size of F2 littermates from aged F1 female rats, as reported previously (Gallo et al. 2012c). Furthermore, DNA damage has also been correlated with deficits in metabolic activity in preimplantation embryos (Sturmy et al. 2009). Collectively, these data are indicative of cell stress responses, and highlight that F2 blastocysts from aged females require more time to adapt, depending on the degree of physiological deficit. Expression of genes related to growth, development and metabolism may have also been exacerbated by advanced maternal age; however, future studies and new cohorts are required to establish this. Future studies characterising maternal metabolic status and uterine fluid composition in early pregnancy in aged females born of normal birth weight and born small may provide mechanistic insights into age-reported effects.

**Transgenerational transmission of growth restriction**

The maternal uterine microenvironment and alterations in pregnancy adaptations can programme the inheritance of diseases to the next generation (Gallo et al. 2012a). How the maternal environment influences the entirety of embryonic, fetal and placental growth, development and function remains unknown. Future studies need to focus on alterations in pregnancy adaptations during all stages from conception to term. Comprehensive biochemical characterisation of F1 follicular and uterine fluid will be necessary to identify key nutrients that may affect oocyte and embryo quality and programme developmental competence.

This study has illustrated that the F2 blastocyst, derived via the maternal line of growth restriction, has alterations in development and metabolism, which has the potential to alter the course of both placental and fetal function and development. A number of mechanisms for transgenerational transmission of diseases have been proposed. These include direct exposure of germ cells from the F1 fetus, inherited through persistent epigenetic modifications of parental germ cells and/or abnormal pregnancy adaptations, which include the development of glucose intolerance during late gestation (Gallo et al. 2012a). The maternal environment could also metabolically programme the embryo via reproductive tract factors, directly affecting embryo function and implantation events. In order to address as to how true
transgenerational transmission occurs, a number of studies need to be applied in light of these new data. These include analyses of the F2 restricted blastocyst derived via the paternal line of transmission, as it would delineate between epigenetic modifications and direct exposure of F1 germ cells to direct influences of the maternal environment and, importantly, characterising the F3 offspring in order to verify true transgenerational transmission.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This study was supported by the NHMRC project grant (APP1045602) to M E Włodek and D K Gardner, N J Hannan received support from the NHMRC Early Career Research fellowship (628927). J S Master was supported by the Fay Marles Scholarship from the University of Melbourne and by an MMI-CSIRO scholarship.

References

www.reproduction-online.org


Torrens C, Poston L & Hanson MA 2009 Transmission of raised blood pressure and endothelial dysfunction to the F2 generation induced by maternal protein restriction in the F0, in the absence of dietary challenge in the F1 generation. British Journal of Nutrition 100 760–766. (doi:10.1017/S00071145090821747)


Received 27 November 2014
First decision 14 January 2015
Revised manuscript received 19 January 2015
Accepted 9 February 2015